Veracyte (Veracyte) Accounts Receivable : $46.7 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Veracyte's accounts receivables for the quarter that ended in Mar. 2024 was $46.7 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Veracyte's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 43.97.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Veracyte's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $2.25.

Veracyte Accounts Receivable Historical Data

The historical data trend for Veracyte's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Accounts Receivable Chart

Veracyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

19.33

18.46

41.46

44.02

40.38

Veracyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															45.49	42.37	39.30	40.38	46.67

Veracyte Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Veracyte Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Veracyte's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	46.665	/	96.844	*	91
=	43.97

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Veracyte's accounts receivable are only considered to be worth 75% of book value:

Veracyte's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(209.188	+	0.75 * 46.665	+	0.5 * 18.328	-	81.424
-	0	-	0)	/	76.4253
=	2.25

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Veracyte Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Veracyte's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte (Veracyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

12V:Germany

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Executives

Phillip G. Febbo	officer: Chief Scientific & Med Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite	officer: Chief Commercial Officer-CLIA	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones	director	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop	director
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson	director, officer: President & CEO	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy	officer: Chief Scientific & Med Officer	338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley	officer: Chief Executive Officer	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant	officer: VP, Chief Accounting Officer	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire	officer: SVP, General Counsel	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers	officer: Chief Financial Officer	3052 ORCHARD DR., SAN JOSE CA 95134